CA
ELV icon

Cullinan Associates’s Elevance Health ELV Stock Holding History

Cullinan Associates’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,700
Closed -$508K – 199
2017
Q2 		$508K Sell
2,700
-50
-2% -$8.98K 0.04% 165
2017
Q1 		$455K Sell
2,750
-3,628
-57% -$577K 0.04% 168
2016
Q4 		$917K Hold
6,378
– – 0.08% 144
2016
Q3 		$799K Buy
6,378
+3,528
+124% +$456K 0.07% 147
2016
Q2 		$374K Buy
2,850
+500
+21% +$68.4K 0.03% 172
2016
Q1 		$327K Sell
2,350
-100
-4% -$13.4K 0.03% 173
2015
Q4 		$342K Hold
2,450
– – 0.03% 172
2015
Q3 		$343K Sell
2,450
-500
-17% -$75.1K 0.03% 187
2015
Q2 		$484K Sell
2,950
-200
-6% -$32K 0.04% 177
2015
Q1 		$486K Buy
+3,150
New +$448K 0.04% 176

Other funds holding ELV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Cullinan Associates's ELV Position: Q3 2017 in Review

Cullinan Associates sold out of Elevance Health (ELV) in Q3 2017, closing a stake of 2,700 shares — an estimated $508K sold.

Cullinan Associates first reported a position in ELV in Q1 2015 and held it in 10 quarters. The position peaked at $917K in Q4 2016. 845 funds tracked by Wall St. Rank hold ELV as of Q3 2017.

  • Cullinan Associates reported no remaining Elevance Health position as of Q3 2017 after selling out during the quarter.
  • Cullinan Associates sold 2,700 Elevance Health shares in Q3 2017, an estimated $508K.
  • Cullinan Associates first reported a position in Elevance Health in Q1 2015 and held it in 10 quarters.
  • Cullinan Associates's Elevance Health position peaked at $917K in Q4 2016.
  • 845 funds tracked by Wall St. Rank held Elevance Health as of Q3 2017.

Based on Cullinan Associates's 13F filing for Q3 2017, filed 16 Oct 2017.